ARROWHEAD PHARMACEUTICALS IN (ARWR)
US04280A1007 - Common Stock
We assign a fundamental rating of 3 out of 10 to ARWR. ARWR was compared to 571 industry peers in the Biotechnology industry. ARWR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ARWR is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ARWR has reported negative net income.
ARWR had a negative operating cash flow in the past year.
ARWR had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: ARWR reported negative operating cash flow in multiple years.
1.2 Ratios
ARWR has a Return On Assets of -60.95%. This is comparable to the rest of the industry: ARWR outperforms 41.80% of its industry peers.
ARWR has a worse Return On Equity (-162.95%) than 65.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -60.95% | ||
| ROE | -162.95% | ||
| ROIC | N/A |
ROA(3y)-24.03%
ROA(5y)-13.77%
ROE(3y)-51.44%
ROE(5y)-28.96%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ARWR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ARWR does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARWR has more shares outstanding than it did 1 year ago.
ARWR has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ARWR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -1.31, we must say that ARWR is in the distress zone and has some risk of bankruptcy.
ARWR has a Altman-Z score (-1.31) which is comparable to the rest of the industry.
ARWR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.31 |
ROIC/WACCN/A
WACC10.34%
2.3 Liquidity
ARWR has a Current Ratio of 4.65. This indicates that ARWR is financially healthy and has no problem in meeting its short term obligations.
ARWR has a Current ratio of 4.65. This is comparable to the rest of the industry: ARWR outperforms 50.97% of its industry peers.
A Quick Ratio of 4.65 indicates that ARWR has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.65, ARWR is in line with its industry, outperforming 52.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.65 | ||
| Quick Ratio | 4.65 |
3. Growth
3.1 Past
The earnings per share for ARWR have decreased strongly by -172.51% in the last year.
The Revenue for ARWR has decreased by -92.33% in the past year. This is quite bad
ARWR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 71.76% yearly.
EPS 1Y (TTM)-172.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.75%
Revenue 1Y (TTM)-92.33%
Revenue growth 3Y39.85%
Revenue growth 5Y71.76%
Sales Q2Q%-100%
3.2 Future
Based on estimates for the next years, ARWR will show a very strong growth in Earnings Per Share. The EPS will grow by 23.70% on average per year.
Based on estimates for the next years, ARWR will show a very strong growth in Revenue. The Revenue will grow by 25.31% on average per year.
EPS Next Y-151.69%
EPS Next 2Y-49.8%
EPS Next 3Y-25.45%
EPS Next 5Y23.7%
Revenue Next Year-71.57%
Revenue Next 2Y-24.42%
Revenue Next 3Y-3.06%
Revenue Next 5Y25.31%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ARWR. In the last year negative earnings were reported.
Also next year ARWR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ARWR's earnings are expected to decrease with -25.45% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-49.8%
EPS Next 3Y-25.45%
5. Dividend
5.1 Amount
ARWR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ARROWHEAD PHARMACEUTICALS IN
NASDAQ:ARWR (11/26/2024, 8:00:01 PM)
After market: 21.6696 +0.62 (+2.94%)21.05
+2.26 (+12.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.62B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -60.95% | ||
| ROE | -162.95% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.65 | ||
| Quick Ratio | 4.65 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-172.51%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-151.69%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-92.33%
Revenue growth 3Y39.85%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y